104 results about "Asthma treatment" patented technology

The present invention provides methods for the assessment, diagnosis, or prognosis of asthma including methods for providing an assessment, diagnosis, or prognosis comprising the step of exposing a sample derived from a patient to an allergen in vitro. The present invention also provides methods for selecting, as well as evaluating the effectiveness of, asthma treatments. The markers of the present invention can be used in methods to identify or evaluate agents capable of modulating marker expression levels in subjects with asthma

The invention relates to an oral preparation of asthma-relieving decoction which is prepared by ginkgo seeds and other eight Chinese medicines mainly for asthma treatment and the preparation method thereof; according to conventional processes, the invention is prepared by mixed tracts (extractum or dry powders and volatile oils), which are utilized as raw materials and formed by ginkgo seeds, ephedra, perilla fruits, coltsfoot flowers, almond, cortex mori, scutellaria, pinellia ternate and glycyrrhiza, together with the vectors or the excipient, which are utilized as matrix and acceptable in pharmacy. The preparation has the efficacies of ventilating lung, lowering qi, clearing away heat and eliminatingsputum and mainly treats wind and cold affecting superficies and ashma causing accumulation of phlegm-heat. The long-term clinical application shows that the oral preparation has a very good therapeutic effects on bronchial asthma and chronic bronchial asthma, etc.

Methods for diagnosing, monitoring and evaluating asthma control in subjects and methods of monitoring the efficacy of asthma treatment regimes in said subjects using blood levels of α-tocopherol quinone.

The present invention relates to methods of asthma treatment and prevention using α_vβ₆ antagonists, such as α_vβ₆-binding antibodies. In particular, the invention relates to the discovery of a correlation between reduced expression of α_vβ₆ and the protection from the increase in airway sensitivity seen in chronic allergen-challenged mice. This protection is associated with protection from the usual allergen-induced increase in airway epithelial mast cells.

The invention discloses a bronchial asthma treatment drug pillow and belongs to the traditional Chinese medicine technical field. The bronchial asthma treatment drug pillow is formed by the following raw materials of, almonds, dried tangerine or orange peel, platycodon root, honeysuckle, mint, ephedra, cloves, herba periliae, cynanchum glaucescens, ageratum, plaster stone, chrysanthemum, as arum and licorice. According to the bronchial asthma treatment drug pillow, the drug can directly act on the head, the lung can be dispersed, the phlegm can be reduced, the cough can be relieved, and accordingly the effects of lung dispersing, phlegm and pus elimination, spleen and stomach warming for cold dispelling and meridian activating for pain stopping are achieved; the bronchial asthma treatment drug pillow is suitable for the chronic bronchial asthma and the effects on the acute bronchial asthma and bronchitis are also achieved; meanwhile various disadvantages and side effects caused by the traditional treatment method are avoided and the asthma treatment effective rate reaches 98%.

The invention discloses application of PD-1H agonists to preparing medicine compositions for preventing or treating asthma of objects. The application has the advantages that treatment is carried out by the aid of agonist type PD-1H monoclonal antibodies, accordingly, the quantities of inflammatory cells (eosinophil and lymphocyte in particular) in mouse BALF (bronchoalveolar lavage fluid) are obviously reduced, pulmonary inflammation and myxopoiesis are obviously reduced, and accordingly the fact that PD-1H can be targeted for treating allergic diseases is indicated by results.

The invention discloses an auxiliary device for treating allergic asthma, and effectively solves the problems that a conventional auxiliary device for treating allergic asthma cannot synchronously exercise upper limbs and lower limbs of a patient, so that the exercise of the patient is limited, the exercise amplitude cannot be adjusted in the exercise process, the conventional auxiliary device cannot adapt to exercise of different patients, the back of the patient cannot be knocked and massaged in the exercise process, and the patient often sits for physical exercise to cause aching pain of the buttocks in the prior art. The auxiliarydevice comprises a supporting frame, a sitting plate is fixedly connected to the upper end of the supporting frame, and a supporting plate is fixedly connected to the upper end of the sitting plate. a swing rod capable of swinging up and down is arranged on the rear side of the upper end of the supporting plate, a movable plate is slidably connected to the upper end of the rear portion of the supporting plate, the right end of the movable plate is rotationally connected with the swing rod, the swing rod swings up and down to achieve left-right movement of the movable plate at the upper end of the supporting plate, and a telescopic rod is fixedly connected to the front end of the swing rod.

Methods for the treatment of asthma are provided, which comprise: (a) providing an implantable or insertable medical device that comprises an asthma treatment agent; and (b) inserting or implanting the medical device within the lungs (e.g., the trachea or the bronchial tree) of a patient, whereupon the therapeutic agent is delivered to the patient in an amount effective to reduce or eliminate the symptoms of asthma. Also disclosed herein are medical devices and kits for carrying out such methods.

The invention belongs to the technical field of medicines, and particularly relates to new application of guanosine, in particular to new application of guanosine in preparation of medicines for treating asthma or inhibitors of MAPK, NF-kappa B and STAT3. The invention aims to solve the problem that safer and more effective asthma treatment medicines need to be developed urgently in the prior art.It is found that in an in-vitro THP-1-derived macrophage inflammation model, guanosine inhibits generation of a proinflammatory factor IL-6 by inhibiting activation of MAPK and NF-kappa B; in an asthma mouse model, guanosine reduces OVA-IgE of mouse plasma, reduces generation of IL-4, IL-6 and IL-13, relieves airway high reactivity, and relieves lung tissue cell infiltration, airway inflammationand collagen deposition. In addition, the expression levels of p-p38 MAPK, p-p65 NF-kappa B, p-I kappa B alpha and p-STAT3 proteins in lung tissues of mice in a guanosine treatment group are obviouslylower than those in an asthma model group. Therefore, the invention provides application of guanosine in preparation of a p38 MAPK inhibitor, a p65 NF-kappa B inhibitor, an STAT3 inhibitor or an asthma treatment drug.

The invention discloses application of tetrahydrocurcumin in treating allergic asthma. The therapeutic action of the tetrahydrocurcumin (THC) on allergic asthma is firstly found and proved; from the perspective of immunity, the THC can be beneficial to alleviating nose allergy and itching, inhibiting lung eosinophilic granulocyte infiltration, reducing lung goblet cell grume generation, reducing lung collagen deposition, and inhibiting Th2 cell factor production, can provide beneficial information for clinic disease evaluation, and has a favorable application prospect in asthma treatment.

The invention discloses an asthma treatment medicine and belongs to the field of traditional Chinese medicines. Effective components of the asthma treatment medicine comprise the following raw materials: lodestone, lophatherum gracile, common coltsfoot flower, dried green bamboo shoot, winchia calophylla, gymnadenia conopsea, slender root of Common Monkshood, fruit of purple perilla, fructus gleditsiae, immature bitter orange, akoda pumpkin, salvia chinensis, Chinese wingnut leaf, radix peucedani, human placenta and Japanese white birch bark. The asthma treatment medicine has the effects of relieving asthma to realize sedation and moistening lung to suppress cough, can quickly treat bronchitis, emphysema, asthma and other diseases, is high in efficiency and cure rate, has the characteristics of strict compatibility, quite mild herbal property and remarkable curative effect, is convenient to take, low in cost, easy to ingest, free from toxic and side effects, can treat both symptoms and root causes, and facilitates large-scale popularization in clinic practice.

The purpose of the invention is to provide a Chinese patent medicine of a lung-warming panting-calming granule for treating cold wheezing during bronchial asthma attack phases. Aiming at the problems of single dosage form and insufficient drug effect research for current applications of traditional Chinese medicines in asthma treatment, the lung-warming panting-calming granule is prepared based on a hospital preparation used in our hospital for years, and the effectiveness and safety of the granule are verified through pharmacological research and clinical research.

The invention discloses a production method of a medicinal wine for treating asthma, aiming at providing a decoction which is fast in asthma treatment speed and low in cost. The technical scheme adopted by the invention is as follows: wide asthma, pericarpium citri reticulatae and folium eriobotryae are soaked at a constant temperature by strong wine. The production method of the medicinal wine for treating asthma is operated according to the following steps: (1) selecting wide asthma, pericarpium citri reticulatae and folium eriobotryae as raw materials; (2) placing the cleaned wide asthma slices, pericarpium citri reticulatae and folium eriobotryae in a jar held with the strong wine, and then sealing the opening of the jar; (3) conveying the sealed jar in a cellar and storing; (4) opening the jar after 80-120 days, and filtering by a medicine sieve to obtain the medicinal wine for treating asthma; and (5) hermetically packaging the medicinal wine for treating asthma by a bottle. The technical scheme adopted by the invention is simple and convenient to operate, and the medicinal wine for treating asthma is fast in asthma treatment speed and low in cost.

The invention relates to the technical field of asthma treatment, and discloses an asthma treatment device for respiratory medicine. The device comprises a bottom plate, a wetting box is arranged on the left side of the bottom plate, an air pipe is arranged on the upper portion of the left side wall of the wetting box, the free end of the air pipe is connected to a mask, a bearing seat is arrangedat the top of the wetting box, the bearing seat is rotationally connected to a rotating disc, a rotating shaft is arranged on the front face of the rotating disc, the rotating shaft is rotationally connected to the right end of a supporting rod, the left end of the supporting rod is rotationally connected to a push rod, the left end of the push rod is connected to a piston, and the piston is slidably connected to interior of an air cavity. The invention is applicable to the asthma treatment device. The piston moving left and right is arranged in the air cavity, the air cavity can continuouslyinject fresh air into the wetting box, a user is treated through the fresh air with liquid medicine, air is blown to the user through the device, the user controls breathing according to the runningrhythm of the device, the user is helped to adapt to the normal breathing rhythm, and the treatment effect is improved.

The invention discloses traditional Chinese medicine for treating bronchial asthma. The traditional Chinese medicine comprises, by weight, 6-8 parts of radix changii, 11-13 parts of prepared licorice root, 10-12 parts of bulbus fritillariae cirrhosae, 5-8 parts of fructus arctii, 2-4 parts of fructus aurantii, 4-5 parts of cortex lycii, 6-7 parts of white atractylodes rhizome, 2-4 parts of semen lepidii, 5-8 parts of earthworm, 5-6 parts of herba lysimachiae, 4-6 parts of loofah roots, 2-4 parts of radix platycodonis, 1-3 parts of radix salviae miltiorrhizae, 5-8 parts of prepared RHIZOMA PINELLIAE with juice of rhizima zingiberis rec-ens, 2-4 parts of fructus rubi, 1-3 parts of ephedra herb, 5-8 parts of tribulus terrestris, 2-4 parts of fructus schisandrae chinensis, 2-4 parts of rhizoma polygonati, 1-3 parts of torricellia angulata flowers and 2-3 parts of herb of hippuris vulgaris L.. The traditional Chinese medicine has the advantages that various medicines are jointly used by means of scientific compatibility, accordingly, effects of eliminating phlegm, stopping cough, removing dampness, activating blood, facilitating lungs, expelling pus and phlegm, relieving asthma, regulating qi to alleviate pain and the like can be realized, excellent bronchial asthma treatment effects can be realized, and the traditional Chinese medicine is made of simple raw materials and convenient to take.